# Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## Methylphenidate (Jornay PM)

#### Notes:

- Adequate trial of a long-acting agent is further defined as wearing off that is not resolved by
  increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR
  clinically significant side effects related to the dosage form that cannot be resolved by adjusting the
  dose or timing.
- \*\*Adequate trial of a short acting agent is further defined as wearing off that is not resolved by
  increasing the dose and the frequency to a minimum of twice daily OR clinically significant side
  effects related to the short-acting dosage form that cannot be resolved by adjusting the dose or
  timing.
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

<u>Initiation (new start) criteria</u>: Non-formulary **methylphenidate (Jornay PM)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
- Patient has failed an adequate trial<sup>^</sup> of a methylphenidate ER (Concerta, Metadate CD, Ritalin LA) (must have at least partial response), with a short-acting agent, unless allergy to an inactive ingredient
- Patient has failed an adequate trial<sup>^</sup> of dexmethylphenidate ER (Focalin XR), with a short-acting agent, unless allergy to an inactive ingredient
- Patient has failed an adequate trial ^ of a long-acting amphetamine product (Adderall XR, etc), with a short-acting agent, unless allergy to an inactive ingredient

<u>Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously</u>: Non-formulary methylphenidate (Jornay PM) will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
- Patient has failed an adequate trial<sup>^</sup> of a methylphenidate ER (Concerta, Metadate CD, Ritalin LA) (must have at least partial response), with a short-acting agent, unless allergy to an inactive ingredient
- Patient has failed an adequate trial<sup>^</sup> of dexmethylphenidate ER (Focalin XR), with a short-acting agent, unless allergy to an inactive ingredient
- Patient has failed an adequate trial ^ of a long-acting amphetamine product (Adderall XR, etc), with a short-acting agent, unless allergy to an inactive ingredient

kp.org

Revised: 06/12/25 Effective: 08/07/25 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



# Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## Methylphenidate (Jornay PM)

<u>Criteria for new members entering Kaiser Permanente already taking the</u> <u>medication who have not been reviewed previously</u>: Non-formulary methylphenidate (Jornay PM) will be covered on the prescription drug benefit when the following criteria are met:


- Patient has a diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
- Patient has failed an adequate trial<sup>^</sup> of a methylphenidate ER (Concerta, Metadate CD, Ritalin LA) (must have at least partial response), with a short-acting agent, unless allergy to an inactive ingredient
- Patient has failed an adequate trial of dexmethylphenidate ER (Focalin XR), with a short-acting agent, unless allergy to an inactive ingredient

#### - OR -

 Patient has a diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD) and patient is age 6 to 20 years old and stable on medication

kp.org

Revised: 06/12/25 Effective: 08/07/25





All plans offered and underwritten by